The synergized diagnostic value of VTQ with chemokine CXCL13 in lung tumors
Virtual Touch Tissue Quantification (VTQ) offers several advantages in the diagnosis of various lung diseases. Chemokine expression levels, such as CXCL13, play a vital role in the occurrence and development of tumors and aid in the diagnosis process. The purpose of this study was to evaluate the co...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1115485/full |
| _version_ | 1827986451857408000 |
|---|---|
| author | Xu Zhang Yejian Lu Kenan Huang Qingfang Pan Youchao Jia Baoshuan Cui Peipei Yin Jianhui Li Junping Ju Xiangyu Fan Rui Tian |
| author_facet | Xu Zhang Yejian Lu Kenan Huang Qingfang Pan Youchao Jia Baoshuan Cui Peipei Yin Jianhui Li Junping Ju Xiangyu Fan Rui Tian |
| author_sort | Xu Zhang |
| collection | DOAJ |
| description | Virtual Touch Tissue Quantification (VTQ) offers several advantages in the diagnosis of various lung diseases. Chemokine expression levels, such as CXCL13, play a vital role in the occurrence and development of tumors and aid in the diagnosis process. The purpose of this study was to evaluate the combined value of VTQ and changes in CXCL13 expression levels for the diagnosis of lung tumors. A total of 60 patients with thoracic nodules and pleural effusion were included, with 30 of them having malignant pleural effusion (based on pathology) and the remaining 30 having benign thoracic nodules and pleural effusion. The relative expression level of CXCL13 was measured in the collected pleural effusions using Enzyme-Linked Immunosorbent Assay (ELISA). The relationship between CXCL13 expression levels and various clinical features was analyzed. A Receiver Operating Characteristic (ROC) curve analysis was conducted on the VTQ results and relative expression levels of CXCL13, and the areas under the curve, critical values, sensitivity, and specificity were calculated. Multivariate analysis incorporating multiple indicators was performed to determine the accuracy of lung tumor diagnosis. The results showed that the expression levels of CXCL13 and VTQ were significantly higher in the lung cancer group compared to the control group (P < 0.05). In the Non-Small Cell Lung Cancer (NSCLC) group, CXCL13 expression levels increased with later TNM staging and poorer tumor differentiation. The expression level of CXCL13 in adenocarcinoma was higher than that in squamous cell carcinoma. The ROC curve analysis revealed that CXCL13 had an area under the curve (AUC) of 0.74 (0.61, 0.86) with an optimal cut-off value of 777.82 pg/ml for diagnosing lung tumors. The ROC curve analysis of VTQ showed an AUC of 0.67 (0.53, 0.82) with a sensitivity of 60.0% and a specificity of 83.3%, and an optimal diagnostic cut-off of 3.33 m/s. The combination of CXCL13 and VTQ for diagnosing thoracic tumors had an AUC of 0.842 (0.74, 0.94), which was significantly higher than either factor alone. The results of the study demonstrate the strong potential of combining VTQ results with chemokine CXCL13 expression levels for lung tumor diagnosis. Additionally, the findings suggest that elevated relative expression of CXCL13 in cases of malignant pleural effusion caused by non-small cell lung cancer may indicate a poor prognosis. This provides promising potential for using CXCL13 as a screening tool and prognostic indicator for patients with advanced lung cancer complicated by malignant pleural effusion. |
| first_indexed | 2024-04-09T23:31:35Z |
| format | Article |
| id | doaj.art-322e9e44a8ba46b99b11e04bf06c20de |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T23:31:35Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-322e9e44a8ba46b99b11e04bf06c20de2023-03-21T05:07:38ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11154851115485The synergized diagnostic value of VTQ with chemokine CXCL13 in lung tumorsXu Zhang0Yejian Lu1Kenan Huang2Qingfang Pan3Youchao Jia4Baoshuan Cui5Peipei Yin6Jianhui Li7Junping Ju8Xiangyu Fan9Rui Tian10Department of Ultrasound, Affiliated Hospital of Hebei University, Baoding, Hebei, ChinaDepartment of Oncology, Hospital of the People’s Liberation Army: 82nd Group Army, Baoding, ChinaDepartment of Oncology, Hospital of the People’s Liberation Army: 82nd Group Army, Baoding, ChinaDepartment of Oncology, Hospital of the People’s Liberation Army: 82nd Group Army, Baoding, ChinaDepartment of Oncology, Affiliated Hospital of Hebei University, Baoding, Hebei, ChinaDepartment of Oncology, Hospital of the People’s Liberation Army: 82nd Group Army, Baoding, ChinaDepartment of Oncology, Hospital of the People’s Liberation Army: 82nd Group Army, Baoding, ChinaDepartment of Ultrasound, Affiliated Hospital of Hebei University, Baoding, Hebei, ChinaDepartment of Radiology, Affiliated Hospital of Hebei University, Baoding, Hebei, ChinaDepartment of Pathology, Affiliated Hospital of Hebei University, Baoding, Hebei, ChinaDepartment of Oncology, Hospital of the People’s Liberation Army: 82nd Group Army, Baoding, ChinaVirtual Touch Tissue Quantification (VTQ) offers several advantages in the diagnosis of various lung diseases. Chemokine expression levels, such as CXCL13, play a vital role in the occurrence and development of tumors and aid in the diagnosis process. The purpose of this study was to evaluate the combined value of VTQ and changes in CXCL13 expression levels for the diagnosis of lung tumors. A total of 60 patients with thoracic nodules and pleural effusion were included, with 30 of them having malignant pleural effusion (based on pathology) and the remaining 30 having benign thoracic nodules and pleural effusion. The relative expression level of CXCL13 was measured in the collected pleural effusions using Enzyme-Linked Immunosorbent Assay (ELISA). The relationship between CXCL13 expression levels and various clinical features was analyzed. A Receiver Operating Characteristic (ROC) curve analysis was conducted on the VTQ results and relative expression levels of CXCL13, and the areas under the curve, critical values, sensitivity, and specificity were calculated. Multivariate analysis incorporating multiple indicators was performed to determine the accuracy of lung tumor diagnosis. The results showed that the expression levels of CXCL13 and VTQ were significantly higher in the lung cancer group compared to the control group (P < 0.05). In the Non-Small Cell Lung Cancer (NSCLC) group, CXCL13 expression levels increased with later TNM staging and poorer tumor differentiation. The expression level of CXCL13 in adenocarcinoma was higher than that in squamous cell carcinoma. The ROC curve analysis revealed that CXCL13 had an area under the curve (AUC) of 0.74 (0.61, 0.86) with an optimal cut-off value of 777.82 pg/ml for diagnosing lung tumors. The ROC curve analysis of VTQ showed an AUC of 0.67 (0.53, 0.82) with a sensitivity of 60.0% and a specificity of 83.3%, and an optimal diagnostic cut-off of 3.33 m/s. The combination of CXCL13 and VTQ for diagnosing thoracic tumors had an AUC of 0.842 (0.74, 0.94), which was significantly higher than either factor alone. The results of the study demonstrate the strong potential of combining VTQ results with chemokine CXCL13 expression levels for lung tumor diagnosis. Additionally, the findings suggest that elevated relative expression of CXCL13 in cases of malignant pleural effusion caused by non-small cell lung cancer may indicate a poor prognosis. This provides promising potential for using CXCL13 as a screening tool and prognostic indicator for patients with advanced lung cancer complicated by malignant pleural effusion.https://www.frontiersin.org/articles/10.3389/fonc.2023.1115485/fullARFIVTQlung tumormalignant pleural effusionCXCL13 |
| spellingShingle | Xu Zhang Yejian Lu Kenan Huang Qingfang Pan Youchao Jia Baoshuan Cui Peipei Yin Jianhui Li Junping Ju Xiangyu Fan Rui Tian The synergized diagnostic value of VTQ with chemokine CXCL13 in lung tumors Frontiers in Oncology ARFI VTQ lung tumor malignant pleural effusion CXCL13 |
| title | The synergized diagnostic value of VTQ with chemokine CXCL13 in lung tumors |
| title_full | The synergized diagnostic value of VTQ with chemokine CXCL13 in lung tumors |
| title_fullStr | The synergized diagnostic value of VTQ with chemokine CXCL13 in lung tumors |
| title_full_unstemmed | The synergized diagnostic value of VTQ with chemokine CXCL13 in lung tumors |
| title_short | The synergized diagnostic value of VTQ with chemokine CXCL13 in lung tumors |
| title_sort | synergized diagnostic value of vtq with chemokine cxcl13 in lung tumors |
| topic | ARFI VTQ lung tumor malignant pleural effusion CXCL13 |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1115485/full |
| work_keys_str_mv | AT xuzhang thesynergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT yejianlu thesynergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT kenanhuang thesynergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT qingfangpan thesynergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT youchaojia thesynergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT baoshuancui thesynergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT peipeiyin thesynergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT jianhuili thesynergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT junpingju thesynergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT xiangyufan thesynergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT ruitian thesynergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT xuzhang synergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT yejianlu synergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT kenanhuang synergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT qingfangpan synergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT youchaojia synergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT baoshuancui synergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT peipeiyin synergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT jianhuili synergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT junpingju synergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT xiangyufan synergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors AT ruitian synergizeddiagnosticvalueofvtqwithchemokinecxcl13inlungtumors |